Search clinical trials for: Treatment B: BGF MDI HFO

Total 674 results

AstraZeneca
Parexel

Not yet recruiting

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Healthy

Germany
AstraZeneca

Recruiting

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants

United States
AstraZeneca

Completed

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Asthma

United States
AstraZeneca

Recruiting

Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants

Mucociliary Clearance

United States
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (LOGOS)

Asthma

United States, China, Czechia, Germany, South Africa, United Kingdom, Mexico, Turkey, Colombia, Russian Federation, Brazil, Israel, Greece, Portugal, Austria, Costa Rica, Saudi Arabia, Slovakia, Sweden, Puerto Rico
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

COPD

United States, Austria, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Peru, Russian Federation, Hungary, China, Taiwan, Australia, Japan, Argentina, South Africa, Belgium, Czechia, Serbia, Poland, Mexico, New... and more
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

COPD

United States
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
AstraZeneca
Parexel

Completed

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
AstraZeneca
Simbec Research

Completed

A Scintigraphy Study of PT010 in COPD Patients (RD708/34000)

Chronic Obstructive Pulmonary Disease

United Kingdom
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Healthy
Karolinska Institutet

Withdrawn

Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery (HODiVA)

Diabetes | Peripheral Arterial Disease | Arterial Occlusive Disease

Sweden
AstraZeneca

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

COPD (Chronic Obstructive Pulmonary Disease)

France, Denmark, Italy, Spain, United States, Canada, Argentina, Japan, Colombia, Germany, Peru, Brazil, China, India, Thailand, Austria, Serbia, Malaysia, Philippines, Poland, Taiwan, Greece, Norway, Sweden, Mexico, Romania, Korea, Republic... and more
Pfizer

Completed

A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

Healthy Volunteers

Belgium
Rigshospitalet, Denmark

Completed

Is it Possible to Treat Cyanide Poisoning With HBO?

Carbon Monoxide Poisoning From Fire Accidents

Denmark
Sunovion

Completed

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

Asthma

United States
Centre of Postgraduate Medical Education

Recruiting

High Tibial Osteotomy With/Without Arthroscopy.

Osteoarthritis, Knee | Meniscus; Degeneration

Poland
Pfizer

Completed

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Arthritis, Rheumatoid

Singapore
Pfizer

Completed

A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers (B0871003)

Pharmacokinetics

Singapore
Hospices Civils de Lyon

Completed

Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach (VISIOTRAIN)

Acquired Visual Field Defects

France
Pfizer

Completed

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

Healthy

United States
Pfizer

Completed

Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Novartis Pharmaceuticals

Completed

Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United Kingdom
Rennes University Hospital

Recruiting

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (DIPLOID)

Pharmacokinetics

France
AstraZeneca
Parexel

Completed

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

Coronary Artery Disease

United Kingdom
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers. (B0871002)

Healthy

Singapore
Dayton Children's Hospital
United States Department of Defense; Kettering Health Network

Terminated

An Evaluation of Hyperbaric Treatments for Children With Cerebral Palsy

Cerebral Palsy | Cerebral Palsy, Spastic

United States
GlaxoSmithKline

Completed

Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma

Asthma

Japan
Altamira Medica Ltd.

Completed

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Rhinitis, Allergic | Perennial Allergic Rhinitis

Canada
University Hospital, Caen

Unknown

Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner (RECOPE)

Heart Disease

France
JW Pharmaceutical

Completed

To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers

Healthy

Korea, Republic of
Pfizer

Completed

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Asthma

Singapore
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Chiesi Farmaceutici S.p.A.

Completed

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Terminated

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

Asthma; Eosinophilic

Bulgaria
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
Celltrion

Completed

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

Health, Subjective

Korea, Republic of
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Pharmacokinetics

Singapore
Pfizer

Completed

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Acromegaly

Canada
Pfizer

Completed

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Karolinska University Hospital
Karolinska Institutet; The Swedish Research Council; Region Stockholm; Swedish... and other collaborators

Active, not recruiting

Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome (HOT-LoCO)

COVID-19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post COVID Condition | Post-Acute COVID-19 Syndrome

Sweden

3

Subscribe